Events & Presentations
Upcoming Webcasts
No webcasts scheduled. Check back soon.
Webcast Archive
-
Leerink Partners Global Biopharma Conference
View Webcast
3:40 p.m. ET - 4:10 p.m. ET -
TD Cowen 44th Health Care Conference
View Webcast
Genetic Medicines Corporate Panel Discussion
2:10 p.m. ET - 3:10 p.m. ET -
Guggenheim 6th Annual Biotechnology Conference
View Webcast
3:00PM-3:25PM ET -
uniQure Huntington's Disease Program Update: AMT-130
View Webcast
8:30 a.m. ET -
uniQure’s Virtual Research & Development Event
View Webcast
8:30AM ET to 10:30 AM ET
Investor Presentations
-
Corporate Presentation – January 2024
View Presentation -
December 2023 Huntington's Disease Program Update AMT-130 – Webcast Presentation
View Presentation -
Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements
View Presentation -
CHDI 2022 – Radiographic and clinical progression after motor diagnosis in HD is a function of initial striatal volume and functional scores: a re-analysis of TRACK-HD/TRACK-ON HD MRI images and data
View Presentation -
ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertions
View Presentation -
EAHAD 2022 – Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderately Severe Hemophilia B
View Presentation -
ESGCT 2022 – linQURE™ platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disorders
View Presentation -
ISTH 2021 – Clinical Outcomes in Adults with Hemophilia B With Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the HOPE-B Trial
View Presentation -
ESGCT 2022 – AAV-miQURE®-mediated targeting of hexanucleotide repeat expansion-containing transcripts in ALS C9orf72 mouse models
View Presentation -
Gene Therapy Information
View Presentation -
ESGCT 2022 – Overexpressing a protective variant while simultaneously lowering toxic APOE as potential treatment for Alzheimer Disease
View Presentation -
ESGCT 2022 – Development of a novel AAV9 gene therapy for the treatment of temporal lobe epilepsy using animal model and human organotypic slices
View Presentation -
ESGCT 2022 – Biodistribution and safety of a novel AAV9 gene therapy for treatment of temporal lobe epilepsy shown in non-human primates
View Presentation -
ESGCT 2022 – Scale-down of AAV production from commercial scale to a high-throughput mini-bioreactor system
View Presentation -
ESGCT 2022 – Impact of bioreactor control parameters on AAV production
View Presentation